Lymphoma | Topics

 
Minority Populations With Aggressive B-Cell Lymphoma Achieved Equitable Estimated Survival Through Equal Access to Care and Nurse Navigation
August 30, 2021

Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.

Promising Responses, Improved Skin-Related QoL Observed With Low-Dose Skin Electron Beam Therapy for Mycosis Fungoides
August 26, 2021

Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.

Second-Line Pembrolizumab Plus Gemcitabine, Vinorelbine, And Liposomal Doxorubicin Demonstrates Efficacy in R/R Classical Hodgkin Lymphoma
August 24, 2021

Pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin appears to be a successful bridging regimen for patients with relapsed/refractory classical Hodgkin lymphoma.

Ixazomib, Rituximab, and Dexamethasone Combo Demonstrates Promising Efficacy in R/R Waldenströms Macroglobulinemia
August 23, 2021

Patients with relapsed/refractory Waldenströms macroglobulinemia benefited from treatment with ixazomib, rituximab, and dexamethasone and maintained a tolerable safety profile.

FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Products Shows Promise in B-Cell Lymphoma
August 20, 2021

FT596 and FT516 natural killer cell products elicited promising responses in a population of patients with B-cell lymphoma.

Bristol Myers Squibb Withdraws Romidepsin R/R Peripheral T-Cell Lymphoma Indication For Lack of Clinical Benefit
August 03, 2021

The accelerated approval status for romidepsin for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma has been withdrawn following the results of the confirmatory phase 3 Ro-CHOP trial.

Zanubrutinib Elicits High Response Rates and Survival Benefit in R/R MCL
August 01, 2021

Zanubrutinib yielded a high response rate and extended progression-free survival in patients with relapsed/refractory mantle cell lymphoma.

Julie Vose, MD, MBA, on the Use of CAR T-Cell Therapy in Lymphomas
July 28, 2021

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

ctDNA Monitoring May Improve Early Relapse Detection in Large B-Cell Lymphoma Following Axi-Cel Treatment
July 23, 2021

For patients with large B-cell lymphoma who have undergone treatment with axicabtagene ciloleucel, ctDNA monitoring may help to improve early detection of recurrent disease.

ZUMA-7 Trial Meets Event-Free Survival End Point in Large B-Cell Lymphoma
June 30, 2021

Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.